Planes, Trains, Automobiles, and Pharmaceuticals

The SONAR program is the only state-funded pharmacovigilance initiative in North America that seeks to identify potentially fatal toxicities of drugs that have not been identified by the regulatory agencies and the pharmaceutical manufacturers. In this presentation, we will review the scientific investigations that led to some of ...
691KB taille 2 téléchargements 444 vues
CENTRE DE RECHERCHE DE ST. MARY PRÉSENTE : ST. MARY’S RESEARCH CENTRE PRESENTS:

Planes, Trains, Automobiles, and Pharmaceuticals: Safety Lessons Learned from the Southern Network on Adverse Reactions ~~~

Charles L Bennett, MD, PhD, MPP Director, Center for Medication Safety Endowed Chair in Medication Safety and Efficacy, South Carolina Center for Economic Excellence in Medication Safety and Efficacy Frank P and Josie M Fletcher Professor of Pharmacy, South Carolina College of Pharmacy Adjunct Professor, Arnold School of Public Health, University of South Carolina Staff Physician, Dorn Veterans Administration Hospital

********************************************************

DATE ET HEURE / DATE AND TIME Le lundi 5 novembre 2012 / Monday Novembre 5, 2012 12:00 -13:00 ENDROIT / LOCATION Auditorium Centre hospitalier de St. Mary / St. Mary’s Hospital Center Un léger dîner sera servi / A light lunch will be served

Bienvenue à tous / Everyone is welcome

ABSTRACT Charles L Bennett MD PhD MPP, South Carolina Center of Economic Excellence Chair for Medication Safety and Efficacy at the South Carolina College of Pharmacy and the Hollings Cancer Center of the Medical University of South Carolina will present an overview of the recent findings from the Southern Network on Adverse Reactions (SONAR). The SONAR program is the only state-funded pharmacovigilance initiative in North America that seeks to identify potentially fatal toxicities of drugs that have not been identified by the regulatory agencies and the pharmaceutical manufacturers. In this presentation, we will review the scientific investigations that led to some of the more recent SONAR findings- including rituximab-associated progressive multifocal leukoencephalopathy, gadodiamide associated nephrogenic systemic fibrosis, erythropoietin and darbepoetin-associated mortality and venous thromboembolism, and ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura. We will also briefly review the first hand investigations that allowed myself, Denis Cournoyer of McGill, Karen Starko of California, and Henrik Thomsen of Copenhagen to identify three rare adverse drug reactions- pure red cell aplasia, nephrogenic systemic fibrosis, and Reye’s syndrome. Finally, we will provide empirical findings that for the first time identify conflicts of interest in pharmaceutical sponsored basic science research- a finding that may help explain why serious adverse drug reactions are so difficult to identify in less than a 10 year period. Cette présentation sera en anglais seulement